Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome

 

 Buy Article Permissions and Reprints

Summary

Mean platelet volume (MPV) has been proposed as a marker of platelet reactivity and cardiovascular risk. Its prognostic significance has not been thoroughly investigated in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). We included 1,041 consecutive patients with NSTE-ACS. Patients were divided in quartiles according to the MPV value on admission (fl) i.e. Q1<7.5; Q2=7.5–8.0; Q3=8.1–8.8; Q4≥8.9. The primary study endpoint was the composite of cardiovascular death and re-myocardial infarction (MI) at one year. Secondary study endpoints were individual cardiovascular death and re-MI. Patients in Q4 were older, had a higher prevalence of previous MI, peripheral artery disease and advanced Killip class compared to patients in Q1-Q3. Elevated MPV levels (Q4) was independently associated with gender, smoking status, platelet count and creatinine level. Overall, 210 patients (20.2%) reached the primary endpoint, 124 (12.1%) died from cardiovascular causes and 125 (12.0%) suffered from re-MI. On multivariable analysis patients in Q4 were at higher risk of primary endpoint (HR=1.41; 95%CI 1.06–1.89; p=0.02) whilst the association with cardiovascular death and re-MI was attenuated. MPV as continuous variable was independently associated with both primary endpoint (HR=1.19; 95%CI 1.06–1.33; p=0.003) and cardiovascular death (HR=1.23; 95%CI 1.06–1.42, p=0.006). The incorporation of MPV into a comprehensive model of risk significantly increased the likelihood ratio chi-square for prediction of both the composite endpoint (p=0.004) and cardiovascular death (p=0.009). Therefore, MPV may be useful to improve risk stratification in NSTE-ACS patients and should be included in future prospective studies evaluating the role of platelet function in promoting cardiovascular events.

• References

• 1 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
  CrossrefPubMedGoogle Scholar
• 2 Angiolillo DJ. et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007; 50: 1541-1547.
  CrossrefPubMedGoogle Scholar
• 3 Breet NJ. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
  CrossrefPubMedGoogle Scholar
• 4 Frere C. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Gurbel PA. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
  CrossrefPubMedGoogle Scholar
• 6 Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease - what does it mean?. Thromb Res 2007; 120: 11-13.
  CrossrefPubMedGoogle Scholar
• 7 Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157-161.
  CrossrefPubMedGoogle Scholar
• 8 Kamath S. et al. Platelet activation: assessment and quantification. Eur Heart J 2001; 22: 1561-1571.
  CrossrefPubMedGoogle Scholar
• 9 Karpatkin S. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 1978; 51: 307-316.
  PubMedGoogle Scholar
• 10 Martin JF. et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
  CrossrefPubMedGoogle Scholar
• 11 Elsenberg EH. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Martin JF. et al. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-1411.
  CrossrefPubMedGoogle Scholar
• 13 Pabon Osuna P. et al. The effect of the mean platelet volume on the short-term prognosis of acute myocardial infarct. Rev Esp Cardiol 1998; 51: 816-822.
  CrossrefPubMedGoogle Scholar
• 14 Huczek Z. et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-290.
  CrossrefPubMedGoogle Scholar
• 15 Estevez-Loureiro R. et al. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2009; 124: 536-540.
  CrossrefPubMedGoogle Scholar
• 16 Kushner FG. et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
  CrossrefPubMedGoogle Scholar
• 17 Chan MY. et al. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation 2009; 119: 3110-3117.
  CrossrefPubMedGoogle Scholar
• 18 Cutlip DE. et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
  CrossrefPubMedGoogle Scholar
• 19 Goncalves SC. et al. Usefulness of Mean Platelet Volume as a Biomarker for LongTerm Outcomes After Percutaneous Coronary Intervention. Am J Cardiol 2011; 107: 204-209.
  CrossrefPubMedGoogle Scholar
• 20 Guthikonda S. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
  CrossrefPubMedGoogle Scholar
• 21 Cesari F. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Huczek Z. et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study. Thromb Res 2010; 125: 406-412.
  CrossrefPubMedGoogle Scholar
• 23 Martin JF, Penington DG. The relationship between the age and density of circulating 51-Cr labelled platelets in the sub-human primate. Thromb Res 1983; 30: 157-164.
  CrossrefPubMedGoogle Scholar
• 24 Hoffman R. Regulation of megakaryocytopoiesis. Blood 1989; 74: 1196-1212.
  PubMedGoogle Scholar
• 25 Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74: 521-525.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Erne P. et al. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost 1988; 59: 259-263.
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Brown AS. et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 802-807.
  CrossrefPubMedGoogle Scholar
• 28 Pizzulli L. et al. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998; 19: 80-84.
  CrossrefPubMedGoogle Scholar
• 29 Kario K. et al. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992; 14: 281-287.
  PubMedGoogle Scholar
• 30 Nadar S. et al. Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 2004; 36: 552-557.
  CrossrefPubMedGoogle Scholar
• 31 Papanas N. et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475-478.
  CrossrefPubMedGoogle Scholar
• 32 Pathansali R. et al. Altered megakaryocyte-platelet haemostatic axis in hypercho- lesterolaemia. Platelets 2001; 12: 292-297.
  CrossrefPubMedGoogle Scholar
• 33 Klovaite J. et al. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost 2011; 9: 49-56.
  CrossrefPubMedGoogle Scholar
• 34 Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006; 27: 2623-2631.
  CrossrefPubMedGoogle Scholar
• 35 Endler G. et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
  CrossrefPubMedGoogle Scholar
• 36 De Luca G. et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 2009; 206: 292-297.
  CrossrefPubMedGoogle Scholar